leisure time -WSS

leisure time

author：explore 2025-09-30 00:08:53 - browse：3134

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Illumina names Agilent executive as new CEO

focus

WSS

Illumina names Agilent executive as new CEO

The 10 drugs up first for Medicare price negotiation

The (many) problems with a new study criticizing cancer screening

Humana sues Biden admin over Medicare Advantage audit rule

Listen: Biogen's potential pivot, & Illumina's next chapter

A new House health package & hospitals’ new site

leisure time

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

Humana sues Biden admin over Medicare Advantage audit rule

Medical leaders decry Supreme Court decision on affirmative action

The (many) problems with a new study criticizing cancer screening

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to fix cancer clinical trials' diversity problem

Tori Bowie and the unacceptable rates of Black maternal death

Why Novartis is changing the name of its research labs

Activists slam private health insurers over coverage restrictions

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

House transparency, PBM reform bill gains bipartisan support

Crinetics acromegaly drug succeeds in late

NIH nominee Bertagnolli will get October confirmation hearing

How generative AI is inspiring dreams of a health data revolution

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

'Make People Better': The CRISPR babies story you probably don't know

entertainment

focus

focus

Wikipedia